IDEAYA Biosciences, Inc. (IDYA) Q1 2022 Earnings Results

IDEAYA Biosciences I Beats on EPS, Stock Up 12.56%

IDEAYA Biosciences I's earnings report shows a positive surprise on EPS, which contributed to a strong stock reaction, rising 12.56%. The company did not provide revenue figures or future guidance, but management's comments suggest they are making progress in their clinical trials. Investors may view the EPS beat as a sign of potential growth ahead.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.36	N/A	+11.76%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their current projects. They emphasized the importance of continued research and development.

Management highlighted ongoing progress in their clinical trials.

They expressed confidence in their research pipeline despite market challenges.

IDEAYA Biosciences I Beats on EPS, Stock Up 12.56%

Key numbers

Management commentary

IDEAYA Biosciences, Inc.

More earnings this week

IDEAYA Biosciences I Beats on EPS, Stock Up 12.56%

Key numbers

Management commentary